Brian Wong, RAPT Therapeutics president and CEO

RAPT Ther­a­peu­tics bol­sters part­ner search with PhII da­ta on small mol­e­cule-Keytru­da com­bo

RAPT Ther­a­peu­tics is of­fer­ing the first look at Phase II da­ta sug­gest­ing that adding its small mol­e­cule CCR4 an­tag­o­nist to Keytru­da is lead­ing to hoped …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.